Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.
Medicina (Kaunas) · 2024
Last updated 2026-05-28In a study of 200 people with type 2 diabetes, those taking liraglutide, empagliflozin, or their combination for 6 months showed improved left atrial function compared to those taking insulin. Specifically, left atrial reservoir strain increased by about 3% in the liraglutide group, 2% in the empagliflozin group, and 2% in the combination group, while it remained unchanged in the insulin group. Changes in left atrial function were also linked to improvements in arterial stiffness and blood pressure.
AI summary of the abstract below.
| Journal | Medicina (Kaunas), 2024 |
|---|---|
| Citations | 12 |
| Relative citation ratio | 2.94 |
| NIH percentile | 84 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are cardioprotective drugs. We investigated their effects on left atrial function, a major determinant of cardiac diastolic dysfunction in type 2 diabetes mellitus. We also explored the association of changes in arterial stiffness with those of the LA strain after treatment. : A total of 200 patients (59.5 ± 9.1 year old, 151 male) with type 2 diabetes mellitus treated with metformin were randomized to insulin (n = 50 served as controls), liraglutide (n = 50), empagliflozin (n = 50) or their combination (liraglutide + empagliflozin) (n = 50). We measured at baseline and 6 months post-treatment: (a) left atrial and global left ventricular longitudinal strain by speckle tracking echocardiography; (b) pulse wave velocity (PWV) and central systolic blood pressure. : At baseline, there was a correlation of the LA reservoir strain with PWV (r = -0.209, = 0.008), central SBP (r = -0.151, = 0.030), EF (r = 0.214, = 0.004) and GLS (r = -0.279, = 0.009). The LA reservoir change 6 months post-treatment was correlated with the PWV change in all groups (r = -0.242, = 0.028). The LA reservoir change 6 months post-treatment was correlated with the GLS change in all groups (r = -0.322, = 0.004). Six months after intervention, patients treated with liraglutide, empagliflozin and their combination improved the left atrial reservoir strain (GLP1RA 30.7 ± 9.3 vs. 33.9 ± 9.7%, = 0.011, SGLT2i 30 ± 8.3 vs. 32.3 ± 7.3%, = 0.04, GLP1&SGLT2i 29.1 ± 8.7 vs. 31.3 ± 8.2, = 0.007) compared to those treated with insulin (33 ± 8.3% vs. 32.8 ± 7.4, = 0.829). Also, patients treated with liraglutide and the combination liraglutide and empagliflozin had improved left atrial conduction strain ( < 0.05). Empagliflozin or the combination liraglutide and empagliflozin showed a greater decrease of PWV and central and brachial systolic blood pressure than insulin or GLP-1RA. ( < 0.05). : Impaired aortic elastic properties are associated with a decreased LA strain in type 2 diabetics. Treatment with liraglutide, empagliflozin and their combination for 6 months showed a greater improvement of left atrial function compared to insulin treatment in parallel with the improvement of arterial and myocardial functions.
Verbatim abstract via PubMed 38541121 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.